BR112012026284A2 - composição de roxitromicina amorfa - Google Patents
composição de roxitromicina amorfaInfo
- Publication number
- BR112012026284A2 BR112012026284A2 BR112012026284A BR112012026284A BR112012026284A2 BR 112012026284 A2 BR112012026284 A2 BR 112012026284A2 BR 112012026284 A BR112012026284 A BR 112012026284A BR 112012026284 A BR112012026284 A BR 112012026284A BR 112012026284 A2 BR112012026284 A2 BR 112012026284A2
- Authority
- BR
- Brazil
- Prior art keywords
- roxithromycin
- amorphous
- composition
- oxy
- peaks
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
composição de roxitromicina amorfa. a presente invenção refere-se a uma composição de macrolídeo, mais particularmante a uma forma amorfa (forma-iii) de 3r, 4s, 5s, 6r, 7r, 9r, 11s, 12r, 13s, 14r-6-[2s, 3r, 4s, 6r)-4-dimetilamino-3-hidróxi-6-metiloxan-2-]óxi-14-etil-7, 12, 13-tri-idróxi-4-[(2r, 4r, 5s, 6s)-5-hidróxi-4-metóxi4,6-dimetiloxan-2-il]óxi-10-(2-metoxietoximetoxi-imino)-3,5,7,9,11,13-hexametil-1-oxaciclotetradecan-2-ona ou roxitromicina, caracterizada pela ausência de picos no espectro infravermelho da forma amorfa (forma-iii) de roxitromicina em 3577, 15, 3526,03, 3465,27 e 3276,24 cm^ -1^ com relação ao espectro infravermelho da matéria-prima de roxitromicina da técnica anterior, que apresenta picos em 3577,15, 3526,03, 3465,27 e 3276,24 cm^ -1^, e adicionalmente caracterizada por uma solubidade aumentada em pelo menos 50% com relação à roxitromicina anidra e moniidratada da técnica anterior em tampão acetato (ph 4,5), tampão fosfato (ph 6,8) e água.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA201002670 | 2010-04-16 | ||
| PCT/IB2011/051621 WO2011128869A1 (en) | 2010-04-16 | 2011-04-14 | Amorphous roxithromycin composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012026284A2 true BR112012026284A2 (pt) | 2016-07-12 |
Family
ID=44120276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012026284A BR112012026284A2 (pt) | 2010-04-16 | 2011-04-14 | composição de roxitromicina amorfa |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8951977B2 (pt) |
| EP (1) | EP2563373A1 (pt) |
| CN (1) | CN102892419B (pt) |
| AU (1) | AU2011241807A1 (pt) |
| BR (1) | BR112012026284A2 (pt) |
| CA (1) | CA2795530C (pt) |
| WO (1) | WO2011128869A1 (pt) |
| ZA (1) | ZA201207441B (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104163840A (zh) * | 2013-08-30 | 2014-11-26 | 郑州后羿制药有限公司 | 一种罗红霉素的精制方法 |
| CN103776945A (zh) * | 2014-01-16 | 2014-05-07 | 扬子江药业集团南京海陵药业有限公司 | 罗红霉素胶囊的质量控制方法 |
| CN106589022B (zh) * | 2016-11-16 | 2019-06-18 | 山东裕欣药业有限公司 | 一种罗红霉素化合物及其制备方法、药物组合物 |
| CN112250723A (zh) * | 2020-10-27 | 2021-01-22 | 黄石世星药业有限责任公司 | 罗红霉素b晶型向a晶型的转变方法 |
-
2011
- 2011-04-14 US US13/640,643 patent/US8951977B2/en not_active Expired - Fee Related
- 2011-04-14 WO PCT/IB2011/051621 patent/WO2011128869A1/en active Application Filing
- 2011-04-14 CN CN201180024588.9A patent/CN102892419B/zh not_active Expired - Fee Related
- 2011-04-14 EP EP11722543A patent/EP2563373A1/en not_active Ceased
- 2011-04-14 AU AU2011241807A patent/AU2011241807A1/en not_active Abandoned
- 2011-04-14 CA CA2795530A patent/CA2795530C/en not_active Expired - Fee Related
- 2011-04-14 BR BR112012026284A patent/BR112012026284A2/pt not_active Application Discontinuation
-
2012
- 2012-10-04 ZA ZA2012/07441A patent/ZA201207441B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2563373A1 (en) | 2013-03-06 |
| US20130102550A1 (en) | 2013-04-25 |
| CN102892419A (zh) | 2013-01-23 |
| WO2011128869A1 (en) | 2011-10-20 |
| CA2795530A1 (en) | 2011-10-20 |
| AU2011241807A1 (en) | 2012-11-08 |
| ZA201207441B (en) | 2013-06-26 |
| US8951977B2 (en) | 2015-02-10 |
| CN102892419B (zh) | 2016-01-06 |
| CA2795530C (en) | 2018-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014017749A8 (pt) | Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo | |
| WO2014007951A3 (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| PH12014502603A1 (en) | D-amino acid compounds for liver disease | |
| ME00585B (me) | Smac peptidomimetici koji se mogu koristiti kao inhibitori aktivnosti iap | |
| BR112012026284A2 (pt) | composição de roxitromicina amorfa | |
| SG150518A1 (en) | Macrolides and methods for producing same | |
| EP2320740A4 (en) | PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR PRODUCING LOW IMPURITY CONCENTRATIONS THEREOF | |
| WO2010139979A3 (en) | Processes for preparing crystalline forms of dasatinib | |
| BR112012031340A2 (pt) | derivados de cianoquinolina | |
| WO2013036783A3 (en) | Methods for treating intrapulmonary infections | |
| WO2012166665A3 (en) | Broad spectrum antibiotics | |
| PL2099769T3 (pl) | Związki 6-okso-1,6-dihydropirymidyn-2-ylowe do leczenia chorób proliferacyjnych | |
| SG10201900541QA (en) | Derivatives of xanthone compounds | |
| BR112013030068A2 (pt) | grânulos de controle biológico estabilizados dispersíveis em água | |
| BR112012008791A2 (pt) | Produção de resíduos comestíveis a partir da produção de etanol. | |
| WO2008110918A3 (en) | Erythromycin-based macrolides | |
| TN2013000377A1 (en) | Thieno [2, 3-d] pyrimidine derivatives and their use to treat arrhythmia | |
| WO2014145713A3 (en) | Aminoglycoside antibiotics with reduced ototoxicity | |
| IN2014DN03010A (pt) | ||
| WO2012177075A3 (ko) | 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물 | |
| TN2015000128A1 (en) | Solid form of dihydro-pyrido-oxazine derivative | |
| WO2014152317A3 (en) | Methods of treating gonorrhea infections using quinolone antibiotics | |
| MX2010006091A (es) | Intermediarios y metodos para hacer analogos de macrolido de zearalenona. | |
| SG178936A1 (en) | Compositions and methods for treating bacterial infections using ceftaroline | |
| WO2009121946A3 (en) | Process for the preparation of optically enriched clopidogrel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
| B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
| B07E | Notice of approval relating to section 229 industrial property law |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Technical examination (opinion): publication of technical examination (opinion) | ||
| B09B | Decision: refusal |